The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Reagents for Food-Borne Pathogens

The Native Antigen Company offers a comprehensive range of reagents for food-borne pathogens, including recombinant and native viral and bacterial antigens, native toxins and strain-specific antibodies.

Antigens & Antibodies for Food-Borne Pathogens

Our antigens for food-borne pathogens include whole cells, native lysates, and recombinant proteins for a range of viral and bacterial species. Our recombinant proteins are produced from a range of expression systems, including mammalian, insect and E. coli, with a range of tags available for ease of purification and binding in assays. We also offer a range of complementary antibodies, including monoclonals and polyclonals raised from various species.

For more information on our antigens and antibodies for food-borne pathogens, click the links in the table below:

E. coli
V. cholerae


Native Toxins and Toxoids

The Native Antigen Company offers a range of highly purified bacterial toxins, used in the development of immunoassays and for the study of disease pathways, including cardiovascular disorders, cancer and diabetes. Each of our toxins are purified directly from cultured bacteria, and undergo several purification steps, followed by toxin-specific bioactivity testing. We also offer formaldehyde-inactivated toxoids that retain their antigenicity, while losing their cytotoxic activity. Our toxins and toxoids are available in a range of formats, including liquid, lyophilised and glycerol.

To see our full range of toxins and toxoids, click the button below:

Norovirus-Like Particles

Virus-like particles (VLPs) comprise the structural proteins of a viral particle, but don’t contain genomic material, making them non-infectious, while presenting all of the structural epitopes of a native virus. Because of these properties, VLPs have been extensively used in diagnostic and vaccine R&D over recent years.

To support norovirus research and development, The Native Antigen Company offers an extended range of 8 norovirus-like particles, produced from our proprietary VirtuE™ (HEK293) and insect-baculovirus expression systems.

Norovirus Electron Micrographs: negative stain EM of norovirus GI.1 VLPs produced by The Native Antigen Company, showing intact particles.

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

13 + 1 =

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases Oxford, UK, 02 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables...

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Preparing for Disease Y: A Better Serological Toolbox

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...

Making Sense of the SARS-CoV-2 Spike Mutations

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...

D614G: Putting the Mutation in Perspective

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...

The Endemic Coronaviruses and What They Might Tell us About COVID-19

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...

Q&A: An Insight Into COVID-19 Serology

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

Coronaviruses: The Next Disease X?

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...